Gerami P, Walling H W, Lewis J, Doughty L, Sontheimer R D
Department of Dermatology, Northwestern University, Chicago, IL, U.S.A.
Br J Dermatol. 2007 Oct;157(4):637-44. doi: 10.1111/j.1365-2133.2007.08055.x. Epub 2007 Jun 26.
Dermatomyositis (DM) presenting during childhood or adolescence classically encompasses hallmark cutaneous changes, proximal muscle weakness, and laboratory evidence of myositis. When cutaneous manifestations of DM are present without muscle weakness for > 6 months, the term 'clinically amyopathic DM' applies (syn. DM sine myositis).
To review the clinical and epidemiological features of published cases of juvenile-onset clinically amyopathic DM, with comparison with adult-onset clinically amyopathic DM and juvenile-onset classical DM.
Systematic review of the published literature.
We identified 68 cases of juvenile-onset clinically amyopathic DM published during 1963-2006. The disease in 18 of 68 (26%) patients subsequently evolved to classical DM. Overall, the mean age at diagnosis was 10.8 years (range 2-17) with nearly equal male/female ratio and mean follow-up of 3.9 years. Among cases with diagnostic testing, 10 of 19 had a positive antinuclear antibody titre, two of nine had elevated erythrocyte sedimentation rate and two of 51 had elevated creatine kinase (CK). Of patients with normal CK, three of 22 had abnormal electromyography, one of 19 had abnormal muscle biopsy, and one of nine had abnormal magnetic resonance imaging. Calcinosis was reported in three of 68. No cases of severe vasculopathy (resulting in ulceration), interstitial lung disease or internal malignancy were reported.
This review suggests a good prognosis for children with clinically amyopathic DM. A minority of patients with negative muscle enzymes had positive ancillary testing for myositis, and these patients rarely developed muscle weakness. Predictive factors for progression to classical DM were not identified. Symptomatic treatment of cutaneous involvement and close clinical monitoring may be an alternative to aggressive immunosuppression.
儿童期或青春期出现的皮肌炎(DM)通常包括典型的皮肤改变、近端肌无力以及肌炎的实验室证据。当DM的皮肤表现存在且无肌无力超过6个月时,术语“临床无肌病性DM”适用(同义词:无肌炎的DM)。
回顾已发表的青少年起病的临床无肌病性DM病例的临床和流行病学特征,并与成人起病的临床无肌病性DM及青少年起病的经典DM进行比较。
对已发表文献进行系统综述。
我们识别出1963年至2006年间发表的68例青少年起病的临床无肌病性DM病例。68例患者中有18例(26%)疾病随后进展为经典DM。总体而言,诊断时的平均年龄为10.8岁(范围2至17岁),男女比例几乎相等,平均随访3.9年。在进行诊断性检查的病例中,19例中有10例抗核抗体滴度阳性,9例中有2例红细胞沉降率升高,51例中有2例肌酸激酶(CK)升高。CK正常的患者中,22例中有3例肌电图异常,19例中有1例肌肉活检异常,9例中有1例磁共振成像异常。68例中有3例报告有钙质沉着。未报告有严重血管病变(导致溃疡)、间质性肺病或内部恶性肿瘤的病例。
本综述提示临床无肌病性DM患儿预后良好。少数肌肉酶阴性的患者肌炎辅助检查呈阳性,且这些患者很少出现肌无力。未确定进展为经典DM的预测因素。皮肤受累的对症治疗和密切临床监测可能是积极免疫抑制治疗的替代方法。